Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Berge, Elisabet O ^a,b   Knappskog, Stian ^a,b   Geisler, Stephanie ^a,g   Staalesen, Vidar ^a,b   Pacal, Marec ^c,d   Børresen Dale, Anne Lise ^e,f   Puntervoll, Pål ^a   Lillehaug, Johan R ^a   Lønning, Per E ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

^g VESTRE VIKEN HOSPITAL TRUST   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; MITOMYCIN; RETINOBLASTOMA PROTEIN;

ALLELIC IMBALANCE; AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; COMPUTER MODEL; CONTROLLED STUDY; EXON; GENE DELETION; GENETIC CONSERVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATIONAL ANALYSIS; POINT MUTATION; PROMOTER REGION; PROTEIN FUNCTION; SEQUENCE ALIGNMENT; WILD TYPE; ALLELE; AMINO ACID SEQUENCE; BREAST TUMOR; FEMALE; GENETICS; HETEROZYGOSITY LOSS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE;

ALLELES; AMINO ACID SEQUENCE; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; EXONS; FEMALE; GENES, RETINOBLASTOMA; HUMANS; LOSS OF HETEROZYGOSITY; MOLECULAR SEQUENCE DATA; POINT MUTATION; PROMOTER REGIONS, GENETIC; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 77955172342     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-173     Document Type: Article

References (41)

1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330. 10.1016/0092-8674(95)90385-2, 7736585.
2. Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008, 100:1771-1779. 10.1093/jnci/djn394, 19066271.
3. Borg A, Zhang QX, Alm P, Olsson H, Sellberg G. The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression. Cancer Res 1992, 52:2991-2994.
4. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 1995, 71:831-835. 2033727, 7710951.
5. Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H, Shuin T. Retinoblastoma gene mutations in primary human prostate cancer. Prostate 1995, 27:314-320. 10.1002/pros.2990270604, 7501543.
6. Zemliakova VV, Zhevlova AI, Strel'nikov VV, Liubchenko LN, Vishnevskaia Ia V, Tret'iakova VA, Zaletaev DV, Nemtsova MV. Abnormal methylation of several tumor suppressor genes in sporadic breast cancer. Mol Biol (Mosk) 2003, 37:696-703.
7. T'Ang A, Varley JM, Chakraborty S, Murphree AL, Fung YK. Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 1988, 242:263-266. 10.1126/science.3175651, 3175651.
8. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 2009, DOI 10.1007/s10549-009-0460-8.
9. Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008, 10:R75. 10.1186/bcr2142, 2614508, 18782450.
10. Trere D, Brighenti E, Donati G, Ceccarelli C, Santini D, Taffurelli M, Montanaro L, Derenzini M. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. Ann Oncol 2009, 20:1818-1823. 10.1093/annonc/mdp209, 19556322.
11. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007, 117:218-228. 10.1172/JCI28803, 1679964, 17160137.
12. Derenzini M, Donati G, Mazzini G, Montanaro L, Vici M, Ceccarelli C, Santini D, Taffurelli M, Trere D. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure. Clin Cancer Res 2008, 14:2199-2209. 10.1158/1078-0432.CCR-07-2065, 18381962.
13. Lonning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR. Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 2007, 18:1293-1306. 10.1093/annonc/mdm013, 17317675.
14. Almasan A, Yin Y, Kelly RE, Lee EY, Bradley A, Li W, Bertino JR, Wahl GM. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci USA 1995, 92:5436-5440. 10.1073/pnas.92.12.5436, 41709, 7777526.
15. Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JY, Knudsen ES. RB-dependent S-phase response to DNA damage. Mol Cell Biol 2000, 20:7751-7763. 10.1128/MCB.20.20.7751-7763.2000, 86358, 11003670.
16. Stengel KR, Dean JL, Seeley SL, Mayhew CN, Knudsen ES. RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents. Cell Cycle 2008, 7:1095-1103.
17. Zagorski WA, Knudsen ES, Reed MF. Retinoblastoma deficiency increases chemosensitivity in lung cancer. Cancer Res 2007, 67:8264-8273. 10.1158/0008-5472.CAN-06-4753, 17804741.
18. Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, Barrera J, Knudsen KE. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res 2007, 67:6192-6203. 10.1158/0008-5472.CAN-06-4424, 17616676.
19. Ianari A, Natale T, Calo E, Ferretti E, Alesse E, Screpanti I, Haigis K, Gulino A, Lees JA. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 2009, 15:184-194. 10.1016/j.ccr.2009.01.026, 2880703, 19249677.
20. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001, 61:2505-2512.
21. Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lonning PE. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003, 9:5582-5588.
22. Lonning PE. Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol 2003, 4:177-185. 10.1016/S1470-2045(03)01022-2, 12623363.
23. Lee JO, Russo AA, Pavletich NP. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 1998, 391:859-865. 10.1038/36038, 9495340.
24. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997, 25:4876-4882. 10.1093/nar/25.24.4876, 147148, 9396791.
25. Bowen C, Spiegel S, Gelmann EP. Radiation-induced apoptosis mediated by retinoblastoma protein. Cancer Res 1998, 58:3275-3281.
26. Knudsen KE, Weber E, Arden KC, Cavenee WK, Feramisco JR, Knudsen ES. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene 1999, 18:5239-5245. 10.1038/sj.onc.1202910, 10498874.
27. Hovig E, Smith-Sorensen B, Gebhardt MC, Ryberg D, Lothe R, Borresen AL. No alterations in exon 21 of the RB1 gene in sarcomas and carcinomas of the breast, colon, and lung. Genes Chromosomes Cancer 1992, 5:97-103. 10.1002/gcc.2870050202, 1381957.
28. Morris EJ, Dyson NJ. Retinoblastoma protein partners. Adv Cancer Res 2001, 82:1-54. full_text, 11447760.
29. Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ, Lassar AB, Kaelin WG. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev 1998, 12:95-106. 10.1101/gad.12.1.95, 316399, 9420334.
30. Kaye FJ, Kratzke RA, Gerster JL, Horowitz JM. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc Natl Acad Sci USA 1990, 87:6922-6926. 10.1073/pnas.87.17.6922, 54650, 2168563.
31. Valverde JR, Alonso J, Palacios I, Pestana A. RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database. BMC Genet 2005, 6:53. 10.1186/1471-2156-6-53, 1298292, 16269091.
32. Yu YS, Kim IJ, Ku JL, Park JG. Identification of four novel RB1 germline mutations in Korean retinoblastoma patients. Hum Mutat 2001, 18:252. 10.1002/humu.1184, 11524739.
33. Blanquet V, Turleau C, Grossmorand MS, Beaufort CS, Doz F, Besmond C. Spectrum of Germline Mutations in the Rb1 Gene - a Study of 232 Patients with Hereditary and Non Hereditary Retinoblastoma. Human Molecular Genetics 1995, 4:383-388. 10.1093/hmg/4.3.383, 7795591.
34. Godefroy N, Lemaire C, Mignotte B, Vayssiere JL. p53 and Retinoblastoma protein (pRb): a complex network of interactions. Apoptosis 2006, 11:659-661. 10.1007/s10495-006-5543-y, 16554964.
35. Lonning PE. Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance. Trends Mol Med 2004, 10:113-118. 10.1016/j.molmed.2004.01.005, 15102353.
36. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2:811-814. 10.1038/nm0796-811, 8673929.
37. Gram IT, Bremnes Y, Ursin G, Maskarinec G, Bjurstam N, Lund E. Percentage density, Wolfe's and Tabar's mammographic patterns: agreement and association with risk factors for breast cancer. Breast Cancer Res 2005, 7:R854-861. 10.1186/bcr1308, 1242160, 16168132.
38. Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS, Lothe RA. Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet 2001, 127:64-70. 10.1016/S0165-4608(00)00433-7, 11408068.
39. Knappskog S, Chrisanthar R, Staalesen V, Borresen-Dale AL, Gram IT, Lillehaug JR, Lonning PE. Mutations and polymorphisms of the p21B transcript in breast cancer. Int J Cancer 2007, 121:908-910. 10.1002/ijc.22777, 17443496.
40. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 2000, 60:1211-1216.
41. Berge EO, Staalesen V, Straume AH, Lillehaug JR, Lonning PE. Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. Biochim Biophys Acta 2010, 1803:386-395. 10.1016/j.bbamcr.2010.01.005, 20080130.